ArticleCell transplantation
Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies.
Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies.Transplantation and cellular therapy · 2024Guideline
- Predictive Models for Toxicities after CAR T-cell Therapy: Challenges and Opportunities.Blood cancer discovery · 2026Review
- Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.Open forum infectious diseases · 2026Article
- Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR.Blood advances · 2025Article
- Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults.Open forum infectious diseases · 2025Article
- Invasive fusariosis after CD19 chimeric antigen receptor T-cell therapy.ASM case reports · 2025Article
- T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.Cancers · 2025Review
- Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients.Pathogens (Basel, Switzerland) · 2025Review
- Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort.Transplantation and cellular therapy · 2025Article
- Mitigating and managing infection risk in adults treated with CAR T-cell therapy.Hematology. American Society of Hematology. Education Program · 2024Review
- The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention.Open forum infectious diseases · 2024Review
- Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Overview of infectious complications among CAR T- cell therapy recipients.Frontiers in oncology · 2024Review
- Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.Haematologica · 2023Review
- Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients.Cancer medicine · 2023Article
- Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.WIREs mechanisms of disease · 2022Review
- Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days.Blood advances · 2021Review
- [Infectious complications following chimeric antigen receptor T-cell therapy for a hematologic malignancy within 28 days].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma.Blood cancer journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor T cells (CAR-Ts) constitute a novel therapeutic strategy for relapsed/refractory B-cell malignancies. With the extensive application of CAR-T therapy in clinical settings, CAR-T-associated toxicities have become increasingly apparent. However, information regarding the associated infections is limited. We aimed to evaluate the incidence of infection during CAR-T therapy and identify the potential risk factors. Especially, we evaluated infections and the associated risk factors in 92 patients. The cohort included patients with acute lymphoblastic leukemia (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.